FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

PM Venner

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
David G McLeod; Paul F Schellhammer; Nicholas J Vogelzang; Mark S Soloway; Roohollah Sharifi; Norman Block; PM Venner; AL Patterson; Michael F Sarosdy; R P Kelley; GJ Kolvenbag
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Michael F Sarosdy; Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Nicholas J Vogelzang; Gerald Chodak; Eric A Klein; J J Schellenger; GJ Kolvenbag
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; J J Schellenger; GJ Kolvenbag
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of PM Venner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

1999: David G McLeod; Paul F Schellhammer; Nicholas J Vogelzang; Mark S Soloway; Roohollah Sharifi; Norman Block; PM Venner; AL Patterson; Michael F Sarosdy; R P Kelley; GJ Kolvenbag
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
The Prostate 1999;40(4):218-24.
1998: Michael F Sarosdy; Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Nicholas J Vogelzang; Gerald Chodak; Eric A Klein; J J Schellenger; GJ Kolvenbag
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Urology 1998;52(1):82-8.
1997: Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; J J Schellenger; GJ Kolvenbag
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Urology 1997;50(3):330-6.
1997: Paul F Schellhammer; PM Venner; Gabriel P Haas; E J Small; P T Nieh; D R Seabaugh; AL Patterson; E Klein; Zev Wajsman; BJ Furr; Y Chen; GJ Kolvenbag
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
The Journal of urology 1997;157(5):1731-5.
1996: Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; Y Chen; GJ Kolvenbag
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Cancer 1996;78(10):2164-9.
1996: Mark S Soloway; Paul F Schellhammer; Roohollah Sharifi; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; J Jones; GJ Kolvenbag
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
European urology 1996;29 Suppl 2():105-9.
1996: Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; J Jones; GJ Kolvenbag
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Urology 1996;47(1A Suppl):54-60; discussion 80-4.
1995: Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; J Jones; GJ Kolvenbag
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Urology 1995;45(5):745-52.